SEARCH:   Advanced

Blood, 1 February 2007, Vol. 109, No. 3, pp. 868-873. Prepublished online as a Blood First Edition Paper on October 10, 2006; DOI 10.1182/blood-2006-08-019083. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2006-08-019083v1 109/3/868    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Bunn, H. F. Search for Related Content PubMed PubMed Citation Articles by Bunn, H. F. Related Collections Hemostasis, Thrombosis, and Vascular Biology Red Cells Free Research Articles Review Articles Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  REVIEWS IN TRANSLATIONAL HEMATOLOGY New agents that stimulate erythropoiesis H. Franklin Bunn1 1 Hematology Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA Recombinant human erythropoietin (rhEpo) has proven to be remarkably safe and effective for treatment of anemias, primarily those secondary to renal disease and malignancy. Despite the worldwide use of rhEpo, concerns about its cost, the need for frequent parenteral administration, and the development of anti-Epo antibodies have prompted development of improved agents to stimulate erythropoiesis. Three strategies appear to be particularly promising. The half-life of Epo in the circulation can be prolonged by the addition of N-linked carbohydrate groups, by formation of adducts with polyethylene glycol, and by preparation of Epo multimers. Second, mimetic peptides can effectively trigger signal transduction at the Epo receptor, thereby boosting red-cell production. Finally, the hypoxia inducible transcription factor (HIF) can be pharmacologically induced by oral agents, resulting in enhanced expression not only of endogenous Epo but also of other genes important in the regulation of erythropoiesis. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: B. Eldridge, R. N. Cooley, R. Odegrip, D. P. McGregor, K. J. FitzGerald, and C. G. Ullman An in vitro selection strategy for conferring protease resistance to ligand binding peptides Protein Eng. Des. Sel., November 1, 2009; 22(11): 691 - 698. [Abstract] [Full Text] [PDF] C. T. Noguchi Where the Epo cells are Blood, May 15, 2008; 111(10): 4836 - 4837. [Full Text] [PDF] M. J. Percy, P. W. Furlow, G. S. Lucas, X. Li, T. R.J. Lappin, M. F. McMullin, and F. S. Lee A Gain-of-Function Mutation in the HIF2A Gene in Familial Erythrocytosis N. Engl. J. Med., January 10, 2008; 358(2): 162 - 168. [Abstract] [Full Text] [PDF] A. Tefferi Pharmaceutical Erythropoietin Use in Patients With Cancer: Is It Time to Abandon Ship or Just Drop Anchor? Mayo Clin. Proc., November 1, 2007; 82(11): 1316 - 1318. [Full Text] [PDF] D. A. Persons A pill for some anemias? Blood, September 15, 2007; 110(6): 1709 - 1709. [Full Text] [PDF] D. W. Grabe Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease Am. J. Health Syst. Pharm., July 1, 2007; 64(13_Supplement_8): S8 - S14. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020